Liu, Dan |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT06128681: Diagnosis and Comprehensive Treatment of Mediastinal Interventional Technique |
|
|
| Recruiting | N/A | 30 | RoW | Intraairway ultrasound-guided mediastinal opening technique | Dan Liu | Mediastinal Diseases | 11/25 | 12/25 | | |
NCT05838183: Interstitial Lung Disease and Obstructive Sleep Apnea |
|
|
| Recruiting | N/A | 70 | RoW | The relationship between imaging and ROSE and NGS, Association between the severity of OSA and biological specimen examination | Dan Liu | ILD OSA | 08/25 | 12/25 | | |
ARTICULAtE, NCT06308120: A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB |
|
|
| Recruiting | N/A | 354 | RoW | Ion Endoluminal System, superDimension Navigation System and Accessories | Intuitive Surgical, Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd | Pulmonary Nodule, Solitary, Lung Cancer | 06/26 | 09/26 | | |
NCT04462185: A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers |
|
|
| Recruiting | N/A | 3000 | RoW | A genomic and transcriptomic landscape analysis | AnchorDx Medical Co., Ltd., The First Affiliated Hospital of Guangzhou Medical University, Tongji Hospital, Qilu Hospital of Shandong University, Shanghai Zhongshan Hospital, West China Hospital, Beijing Chao Yang Hospital, Johnson & Johnson (China) Investment Ltd. | Pulmonary Nodules | 06/24 | 12/24 | | |
NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules |
|
|
| Active, not recruiting | N/A | 10560 | RoW | ctDNA methylation analysis by NGS | AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University | Pulmonary Nodules | 09/24 | 06/25 | | |
NCT06572540: Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer |
|
|
| Not yet recruiting | N/A | 110 | RoW | Transthoracic cryoablation, Transbronchial cryoablation | Jiayuan Sun | Lung Cancer | 12/25 | 12/28 | | |
Wang, Caili |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
| Active, not recruiting | 3 | 404 | Europe, Canada, Japan, US, RoW | Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo | Chinook Therapeutics, Inc. | IgA Nephropathy, Immunoglobulin A Nephropathy | 12/26 | 12/26 | | |
NCT05885737: Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus |
|
|
| Active, not recruiting | 3 | 260 | RoW | Difelikefalin Injection, Placebo Injection | Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd | Uremic Pruritus | 07/25 | 07/25 | | |
NCT05136456: Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy |
|
|
| Active, not recruiting | 2 | 61 | RoW | SHR1459 Low Dose, SHR1459 High Dose, Placebo | Reistone Biopharma Company Limited | Primary Membranous Nephropathy | 08/23 | 03/24 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
Wang, Yongfu |
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 140 | RoW | Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group | Tianjin Hemay Pharmaceutical Co., Ltd | Rheumatoid Arthritis | 06/23 | 06/23 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody(JS005), Placebo(JS005) | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
| Recruiting | 2 | 532 | Europe, Japan, US, RoW | M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
Liu, Shengjun |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |